Serum procalcitonin as a marker of neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD).
Clinics (Sao Paulo)
; 79: 100383, 2024.
Article
en En
| MEDLINE
| ID: mdl-38797123
ABSTRACT
BACKGROUND:
Neonatal Intrahepatic Cholestasis (NICCD), as the early-age stage of Citrin deficiency involving liver dysfunction, lacks efficient diagnostic markers. Procalcitonin (PCT) has been identified as a biomarker for infection as well as various organ damage. This study aimed to explore the potential of PCT as a biomarker for NICCD.METHODS:
In a single-center retrospective case-control study. Serum PCT concentrations before and after treatment of 120 NICCD patients, as the study group, were compared to the same number of cholestatic hepatitis patients, as the control group. The potential value of PCT to discriminate NICCD from control disease was further explored using Receiver Operating Characteristic (ROC) curve analysis and compared to those of other inflammatory markers.RESULTS:
There was a significantly higher level of PCT in NICCD patients than in the control group. PCT concentrations were only weakly correlated with neutrophil counts and CRP levels (p Ë 0.05). At a cut-off value of 0.495 ng/mL, PCT exhibited a significantly higher diagnostic value compared to other inflammatory markers for discriminating NICCD from the control, with a sensitivity of 90.8 % and specificity of 98.3 %.CONCLUSION:
PCT might be used as an initial biomarker to discriminate children with NICCD from another hepatitis disease.Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Biomarcadores
/
Colestasis Intrahepática
/
Curva ROC
/
Citrulinemia
/
Polipéptido alfa Relacionado con Calcitonina
Límite:
Female
/
Humans
/
Infant
/
Male
/
Newborn
Idioma:
En
Revista:
Clinics (Sao Paulo)
Asunto de la revista:
MEDICINA
Año:
2024
Tipo del documento:
Article
País de afiliación:
China